HDAC9 and cancer: The role of HDAC-inhibitors to augment immunotherapeutic responses against ES, e.g., by up-regulating immune checkpoint inhibitors is subject to current investigation in the Individualized Therapy For Relapsed Malignancies in Childhood (INFORM) trials [14].